<DOC>
	<DOCNO>NCT00556439</DOCNO>
	<brief_summary>Giant cell arteritis ( GCA ) Takayasu 's arteritis ( TAK ) diseases cause swell artery head , neck , upper body , arm . TAK specifically affect aorta , large blood vessel body , branch . Therapies available improve symptom GCA TAK , relapse often occur , good treatment need . Abatacept drug interacts certain cell body involve GCA TAK . This study evaluate effectiveness abatacept treat GCA TAK prevent disease relapse .</brief_summary>
	<brief_title>Abatacept Treating Adults With Giant Cell Arteritis Takayasu 's Arteritis</brief_title>
	<detailed_description>GCA TAK cause inflammation line artery , interfere body 's ability carry oxygen area need . Symptoms GCA include headache , jaw pain , blur double vision . Serious symptom occur less commonly blindness stroke . TAK symptom include fever , fatigue , weight loss , arthritis , non-specific ache pain . There may also tenderness near affected artery . Researchers believe GCA TAK diseases control body 's immune system . Activated T-cells , specifically , critical origin development disease . Abatacept medication modulate signal require T-cell activation . This study evaluate safety effectiveness abatacept treat GCA TAK prevent disease relapse . Participation study may last 4 year . Participants receive abatacept intravenously specify day Months 1 , 2 , 3 . They also receive daily prednisone , start dose 40 60mg , taper 20mg Month 3 , finally taper discontinuation reach . At Month 3 , participant achieve remission randomly assign double-blind condition either continue abatacept switched placebo infusion . Both treatment give month study visit . Blood sample also collect monthly study visit conduct laboratory-based study . Participants remain remission continue receive abatacept placebo monthly common closing date , define 12 month enrollment 33rd participant disease .</detailed_description>
	<mesh_term>Arteritis</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Takayasu Arteritis</mesh_term>
	<mesh_term>Aortic Arch Syndromes</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis GCA TAK ( define ) History active GCA TAK within past 2 month Age 15 year old Willing use effective mean birth control throughout study Specific Inclusion Criteria Participants GCA : Participants must meet three follow five criterion , include either Criterion 4 5 : 1 . Age disease onset equal great 50 year 2 . Disease onset recent experience new type localize pain head 3 . Erythrocyte sedimentation rate great 40mm first hour , determine use Westergren method 4 . Temporal artery abnormality ( i.e. , temporal artery tenderness palpation decrease pulsation , unrelated arteriosclerosis cervical artery ) 5 . Temporal artery large vessel biopsy show vasculitis characterize predominance mononuclear cell infiltration granulomatous inflammation , usually multinucleated giant cell characteristic change large vessel stenosis aneurysm arteriography Specific Inclusion Criteria Participants TAK : Presence abnormality consistent TAK identify use arteriography , plus least one follow criterion : 1 . Age disease onset less 50 year 2 . Pain legs arm 3 . Decreased brachial artery pulse ( one artery ) 4 . Difference 10mm Hg blood pressure arm 5 . Bruit subclavian artery aorta Evidence active infection ( include chronic infection ) Pregnant breastfeed HIV infect , hepatitis C infect , positive hepatitis B surface antigen Inability comply study guideline Inability provide inform consent Cytopenia , define platelet count less 80,000/mm3 , absolute neutrophil count less 1,500/mm3 , hematocrit le 20 % Insufficient kidney function , define serum creatinine 3 mg/dL creatinine clearance 20 ml/min less Other uncontrolled disease could prevent safe study completion History malignant neoplasm except adequately treat basal squamous cell carcinoma skin solid tumor treat curative therapy diseasefree least 5 year Receipt investigational agent device within 30 day prior study entry A live vaccination within 4 week prior study entry Presence positive tuberculin skin test induration least 5mm Radiographic evidence suggestive tuberculosis Poor tolerability blood draw lack adequate access vein medication administration blood draws History treatment rituximab within 12 month prior study entry history treatment rituximab 12 month prior study entry , B lymphocyte count return normal History treatment infliximab within past 49 day , adalimumab within past 28 day , etanercept within past 21 day . Presence follow disease condition : 1 . Microscopic polyangiitis 2 . ChurgStrauss syndrome 3 . Polyarteritis nodosa 4 . Cogan 's syndrome 5 . Behcet disease 6 . Sarcoidosis 7 . Kawasaki disease 8 . Tuberculosis atypical mycobacterial infection 9 . Deep fungal infection 10 . Lymphoma , lymphomatoid granulomatosis , type malignancy mimic vasculitis 11 . Cryoglobulinemic vasculitis 12 . Systemic lupus erythematosus 13 . Rheumatoid arthritis 14 . Mixed connective tissue disease overlap autoimmune syndrome</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>Arteritis</keyword>
	<keyword>Takayasu 's</keyword>
	<keyword>Temporal Arteritis</keyword>
	<keyword>Abatacept</keyword>
</DOC>